会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
    • ALPHA-肾上腺素和多巴胺,组胺,咪唑啉和血清素受体及其使用配体
    • EP2236511A2
    • 2010-10-06
    • EP08864305.1
    • 2008-12-19
    • Alla Chem, LLC.Ivashchenko, Andrey Alexandrovich
    • IVASHCHENKO, Andrey AlexandrovichIVASHCHENKO, Alexander VasilievichLAVROVSKY, Yan VadimovichMITKIN, Oleg DmitrievichSAVCHUK, Nikolay FilippovichTKACHENKO, Sergey YevgenievichOKUN, Ilya Matusovich
    • C07D471/04C07D487/04A61K31/43A61K31/519A61P25/00
    • C07D471/04C07D487/04
    • The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT 7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates,

      wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C 1 -C 4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C 1 -C 4 alkyl, CF 3 , CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH 2 ) m group, optionally substituted CH=CH group, optionally substituted CH 2 -CH=CH group, C≡C group, SO 2 group; n = 1, 2; m = 1, 2, 3; solid line accompanied by dotted line, i.e. ( --- ) may represent single or double bond.
      The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.
    • 本发明涉及新的配体的生物学活性的广谱都包括同时±肾上腺素能受体,多巴胺受体,组胺受体,咪唑啉受体和血清素受体,其中血清素5-HT 7种受体,它们是在通式1的化合物 的游离碱,几何异构体,外消旋混合物或单独的光学异构体,药学上可接受的盐和/或水合物,形式worin:R 1是氨基,选自氢,任选取代的C 1 -C 4烷基,酰基,杂环基的取代基, 烷氧基羰基,取代的磺酰基; R2是环体系,选自氢,卤素,任选取代的C 1个-C 4烷基,CF 3中选择的取代基,CN,烷氧基,烷氧基羰基,羧基,杂环基或取代的磺酰基; Ar是芳基OPTIONALLY substituiertem不一定安娜迟来与杂环基,或任选取代的芳族杂环基; W是任选substituiertem(CH 2)M基,任选substituiertem CH = CH基团,任选substituiertem CH 2 -CH = CH基团,C‰¡C组,SO 2基团; n = 1时,2; M = 1,2,3; solidLine陪同下虚线,即 (---)可以代表单键或双键。 因此,本发明涉及活性成分,药物组合物包含所述的配位体作为活性成分; 用于治疗的疾病和人类和温血动物的中枢神经系统(CNS)的条件下有用的新的药物。
    • 5. 发明公开
    • SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF
    • 取代的3-芳基磺酰基 - 吡唑并[1,5-A]嘧啶,血清素5-HT6受体拮抗剂和方法的生产和使用
    • EP2351756A1
    • 2011-08-03
    • EP09819452.5
    • 2009-10-06
    • Ivashchenko, Andrey AlexandrovichAlla Chem, LLC.
    • IVASHCHENKO, Alexander VasilievichSAVCHUK Nikolay FilippovichLAVROVSKY YanMITKIN, Oleg DmitrievichKADIEVA Madina Georgievna
    • C07D487/04A61K31/519A61P25/28A61P25/18A61P25/26A61P25/16A61P25/08A61P9/10A61P3/04A61P3/08A61K9/48A61K9/08
    • C07D487/04
    • The invention relates to the novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, serotonin 5-HT 6 receptor antagonists and pharmaceutical compositions, and also to method for prophylaxis and treatment of various diseases of central nervous system at humans and warm-blooded animals pathogenesis of which is associated with serotonin 5-HT 6 receptors, in particular, Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and other neurodegenerative diseases, cognitive disorders and obesity.
      In the general formula 1:

      wherein: X = S, SO or NH; R 1 represents hydrogen, optionally substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl or heterocyclyl; R 2 represents hydrogen, halogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, aryldiazenyl or optionally substituted amino group; R 3 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, pyridyl or optionally substituted amino group, besides, in cases when X = S or X = NH, at least one of R 1 , R 2 or R 3 represent substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl, heterocyclyl, halogen, substituted hydroxyl, optionally substituted amino group, aryldiazenyl, or at least two of R 1 , R 2 or R 3 represent hydrogen; R 4 represents C 1 -C 3 alkyl; R 5 represents hydrogen, one or two halogens, C 1 -C 3 alkyl or optionally substituted hydroxyl.
    • 本发明涉及新颖的substituiertem 3-芳基磺酰基 - 吡唑并[1,5-A]通式1的嘧啶,其药学上可接受的盐和/或水合物,五羟色胺5-HT 6受体拮抗剂和药物组合物,并且因此方法 用于特别是在人类和温血动物的所有发病预防和治疗中枢神经系统的各种疾病的,其与血清素5-HT 6个受体相关的疾病,阿尔茨海默氏症,帕金森氏病,亨廷顿氏病,精神分裂症,以及其它神经变性疾病, 认知障碍和肥胖。 在通式1:其中:X = S,SO或NH; 的R 1 darstellt氢,任选取代的C 1 -C 3烷基,环烷基,金刚烷基,芳基或杂环基; R 2 darstellt氢,卤素,任选取代的C 1 -C 3烷基,取代的羟基,或aryldiazenyl任选取代的氨基; ,R 3 darstellt氢,任选取代的C 1 -C 3烷基,取代的羟基,吡啶基或任选取代的氨基基团,此外,在情况下,当X = S或X = NH,R 1,R中的至少一个2或R 3代表 取代的C 1 -C 3烷基,环烷基,金刚烷基,芳基,杂环基,卤素,取代的羟基,任选取代的氨基,aryldiazenyl,或至少两个R 1,R 2或R 3表示氢; ,R 4 darstellt C 1 -C 3烷基; 的R 5 darstellt氢,一个或两个卤素,C 1 -C 3烷基或任意取代的羟基。